Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
Dawson James Reiterates Sorrento Therapeutics (SRNE) at Buy, $16 PT, Sees 70% Chance of Success of Company's COVID Tests and Therapeutics
-
BMO Capital Reiterates Bristol-Myers Squibb (BMY) Outperform, Bempeg in Melanoma Was Incremental to BMY's Thesis
-
Mizuho Securities Reiterates Buy Rating on Nektar Therapeutics (NKTR), Expects Weakness in NKTR Shares
-
Stifel Reiterates Nektar Therapeutics (NKTR) at Buy, But Expects Deflation in Stock, Sees NKTR-358 as Lead Asset Going Forward
-
Oppenheimer Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
-
Needham & Company Reiterates Buy Rating on Cara Therapeutics (CARA)
-
Cantor Fitzgerald Reiterates Novan (NOVN) at Overweight, Sees EPI Acquisition as "Smart and Significant Move"
-
Stifel Reiterates Reiterates Dyne Therapeutics (DYN) at Buy, DMD Trial Hold Remains Biggest Concern
-
Dawson James Reiterates Buy Rating on Lineage Cell Therapeutics Inc. (LCTX), Dry AMD Remains Key Opportunity
-
William Blair Reiterates Docusign (DOCU) at Outperform, Sales Restructuring is Concerning, but Company has Large Market Opportunity and Enjoys Strong Secular Growth Trends
-
Needham & Company Reiterates Hold Rating on Amphastar Pharmaceuticals (AMPH)
-
Cantor Fitzgerald Reiterates Overweight Rating on AxoGen (AXGN)
-
Needham & Company Reiterates Buy Rating on Geron Corporation (GERN)
-
Mizuho Securities Reiterates Selecta Biosciences (SELB) at Buy
-
Needham & Company Reiterates Selecta Biosciences (SELB) at Buy
-
Needham & Company Reiterates Autolus Therapeutics plc (AUTL) at Buy, Views Clinical Profile of obe-cel as Potentially Best-in-Class
-
Needham & Company Reiterates Zealand Pharma (ZEAL) at Buy, Short Bowel Syndrome Program Remains Main Value Driver
-
Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy Ahead of April 5th PDUFA, Analysts Expects Approval and Sees Company Well Prepared for Commercial Launch
-
Raymond James Starts Nkarta Inc. (NKTX) at Outperform, $17 Price Target
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
-
Needham & Company Reiterates Hold Rating on Graybug Vision (GRAY)
-
Genocea Biosciences (GNCA) PT Raised to $4.70 at Stifel, Believes Too Much Skepticism is Priced in for GEN-011
-
H.C. Wainwright Reiterates Buy Rating on Progenity (PROG) Following DDS Safety Data
-
Cantor Fitzgerald Reiterates TherapeuticsMD (TXMD) at Overweight, "TXMD's Opportunity to Become Leading Women's Healthcare Company Remains Underappreciated"
-
Mizuho Securities Reiterates Buy Rating on Autolus Therapeutics plc (AUTL)
-
Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $42 at Needham & Company, Analyst Maintains Buy Rating on Optimistic Tone on Company's Programs
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA), Phase 2 Initiation Supports Moderna's Competitive Positive in the Market
-
Dawson James Reiterates Buy Rating, $10 Price Target on Bluejay Diagnostics (BJDX)
-
Truist Securities Reiterates Vertex (VRTX) at Buy, $341 PT, Sees Potential Upside From Upcoming Crispr's Diabetes Read-Through
-
Raymond James Reiterates Market Perform Rating on Acadia Pharmaceuticals (ACAD), "A Panel is a Negative Indicator for Approval"
-
Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List; Amgen (AMGN) and PDS (PDSB) Seeing Biggest Increases
-
Stifel Upgrades Ideaya Biosciences (IDYA) to Buy, Sees Risk/Reward Skewed to the Upside
-
Brookline Capital Markets Reiterates Intellia Therapeutics (NTLA) at Buy, Estimates NTLA-5001 Peak Sales of $2.6B
-
Lyra Therapeutics (LYRA) Reiterated at Outperform by William Blair, Company Poised to Become a Major Player, Significant Disconnect in Valuation Exists, Remains Favorite Small-Cap Name,
-
Cantor Fitzgerald Reiterates Lipocine (LPCN) at Overweight, Company's Pipeline Assets and Peak Sales Opportunities are Underappreciated
-
Dawson James Reiterates Buy Rating on CytoSorbents (CTSO)
-
Needham & Company Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD), Sees 50% Chance of pimavanserin Approval in Alzheimer's
-
H.C. Wainwright Reiterates Buy Rating on Paratek Pharmaceuticals (PRTK), Cites Impressive Preclinical Results in MAC Lung Infections
-
Stifel Reiterates Repare Therapeutics (RPTX) at Buy, RP-3500 Safety Profile Raises Some Concerns, but Optimistic its Combination with PARPI's is Feasible
-
Mizuho Securities Reiterates Relmada Therapeutics Inc (RLMD) at Buy, Remains Confident in Likelihood of Success of Ongoing Phase 3
-
Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy, "We Believe Biologically Onpattro Should be Best-in-Class"
-
Sage Therapeutics (SAGE) PT Lowered to $40 at Truist Securities on Negative KOL Commentary, Expects FDA to Require Additional Trial
-
Needham & Company Reiterates Revance Therapeutic (RVNC) at Buy, BLA Resubmission Timing is a Welcome Surprise, RVNC Remains Conviction List Top Pick
-
William Blair Reiterates Revance Therapeutic (RVNC) at Outperform, Sees DAXI as a Blockbuster in the Making, Believes Approval is an Eventuality
-
Dawson James Reiterates Can-Fite (CANF) at Buy with $5 PT Ahead of Psoriasis Data
-
Mizuho Securities Reiterates Revance Therapeutic (RVNC) at Buy, Sees FDA Daxi Decision in September 2022
-
Truist Securities Reiterates Buy Rating on AnaptysBio (ANAB), Views Risk/Reward as Skewed to Upside
-
Needham & Company Reiterates Buy Rating on Cidara Therapeutics (CDTX)
-
Acumen Pharmaceuticals, Inc. (ABOS) PT Lowered to $17 at Stifel
-
Cantor Fitzgerald Reiterates Cidara Therapeutics (CDTX) at Overweight, Believes the Street Underappreciates Company's Sales Potential, Sees Upward Earnings Revisions
